Cancer Drug Discovery: How Far Have We Come, Where Are We Stuck, and What Comes Next?
In this article
Remarkable Progress in Oncology and the Gaps That Need Addressing
Progress in cancer treatment is a success story beginning with the first effective drugs in the 1940s and reaching its current peak with immunotherapies. Mechlorethamine and methotrexate began a journey that made deadly diseases such as Hodgkin lymphoma and childhood acute leukemia (ALL) treatable.
Thanks to the scientific explosion over the past 50 years — particularly the last 20 — in 2019–2022 alone, 52 new anticancer agents were approved. This has made oncology both exciting and rewarding. However, the current system often overlooks critical scientific areas needed to optimize treatment in practice.
📊 A Quick Numerical Summary
- First cancer drug (Mechlorethamine): 1946
- First targeted therapy (Imatinib): 2001
- First immunotherapy (CTLA-4 inhibitor): 2011
- Number of drugs approved in 2019–2022: 52
- 2024 global oncology drug market: 179 billion USD
Why Does This Matter?
Although rapid advances in cancer treatment are promising, progress is not always "smart" or "equitable." Areas such as circadian rhythms, microbiome effects, genetic ancestry differences, and rational drug combination design are still not addressed systematically. The oncology of the futurewill be more effective and humane to the extent that we fill these gaps.
A Brief History of Cancer Drug Development: From Severe Toxicity to Cure
Cancer drugs tell the story of a science born from the horrors of war. In the 1940s during World War II, soldiers exposed to mustard gas suffered lymphatic tissue and bone marrow damage. Researchers' realization that this effect could be used against cancer cells marked a turning point. Thus emerged Mechlorethamine , the first chemotherapeutic agent.
Around the same time, Dr. Sidney Farber noticed that folate accelerated leukemia cell growth and developed folate antagonists (aminopterin and methotrexate). These produced the first temporary remissions in childhood leukemia and laid the foundation of modern oncology.
🧩 Chronological Milestones
- 1946: Mechlorethamine – the first effective cytotoxic agent
- 1948: Aminopterin – the first remission in childhood ALL
- 1960s: The concept of combination chemotherapy emerged
- 1970: DeVita and colleagues – cure in Hodgkin lymphoma
- 1971: Pinkel and team – childhood ALL cure rate reached 50%
- 1977: Einhorn – lasting cure of testicular cancer with cisplatin
Initially, these drugs' high toxicity sparked major controversy. In the 1960s, however, pioneering clinicians advocated combining drugs . Considered unethical at the time, this approach quickly became a proven strategy.
In the 1970s, cures achieved in Hodgkin lymphoma by Vincent DeVita and his team, and in childhood ALL by Donald Pinkel, symbolized the triumph of modern chemotherapy. Cisplatinbrought lasting cure rates in testicular cancer to around 90% — for the first time in cancer history, a metastatic disease could be completely cured.
Why Does This Matter?
This period marked modern oncology's transition from "trial and error" to an era of treatment guided by scientific hypotheses . Studies conducted in 1970–1980 introduced not only new drugs but also the concepts of combination, dosing, and resistance to the literature. Many protocols used today (such as ABVD, MOPP, FOLFOX) are the legacy of this period.
Continued Progress and Cost Dynamics in Oncology Drug Discovery
Over the past two decades, oncology has witnessed the fastest drug development period in history. Particularly after 2010, understanding molecular targets and discovering immune checkpoint inhibitors doubled the rate of drug approvals . This progress, however, brought commercial as well as scientific transformation.
📊 Global Oncology Drug Market – Key Indicators
| Year | Number of Newly Approved Drugs | Global Market Size (USD) | Average Cost of Developing One Drug |
|---|---|---|---|
| 2000–2009 | 19 | ≈ 50 billion | ~800 million $ |
| 2010–2018 | 34 | ≈ 120 billion | ~1.3 billion $ |
| 2019–2022 | 52 | ≈ 179 billion | ~2.2 billion $ |
Sources: IQVIA Global Oncology Trends Report (2023), JAMA Oncol. 2025;11:310-316.
The 52 new agents approved in 2019–2022 represent an unprecedented acceleration in oncology. What stands out, however, is that this pace is driven more by market incentives than scientific need . Approval is shortened through "accelerated approval" status, but drugs often enter the market before their long-term clinical benefit has been adequately assessed.
Meanwhile, drug development costs have risen dramatically. A drug costing an average of 800 million dollars to develop in the 2000s now costs over 2 billion. A substantial part of this increase comes from patent competition, marketing budgets, and ownership disputes . In other words, it is not scientific cost, but the system's own bureaucracy that inflates prices.
An Analytical View – "Progress or Paradox?"
- 🔹 Scientific progress has outpaced clinical validation.
- 🔹 New drugs mostly target the same biological targets → "copycat innovation" rather than novelty.
- 🔹 Postapproval optimization studies (dose, combination, patient subgroup) are generally incomplete.
- 🔹 Companies prefer filing for a new molecule to asking "which is less toxic and more effective?"
Oncology drug discovery has therefore become less a scientific marathonthan a financial sprint . Changing this picture is a shared responsibility of researchers, clinicians, and regulators. True innovation lies not only in producing a new molecule, but in fully using the potential of existing drugs as well.
Important Overlooked Problems in Drug Development
Despite their strong potential to improve efficacy, the following four themes are systematically underrepresented in the development cycle.
⏰ Chrono-Oncology: "Not just what is given, but when it is given"
Drug absorption, metabolism, DNA repair, immune mediators, and toxicity thresholds fluctuate with circadian rhythms. For agents such as oxaliplatin, cisplatin, doxorubicin, and 5-FU, administration times may therefore affect clinical outcomes and tolerability.
- Evidence at a glance: randomized multicenter studies reported changes in toxicity profiles with chronotherapy ; effects may differ by drug, age, sex, and performance status.
- Practical benefit: potential to reduce fatigue, neurotoxicity, and GI toxicity in dose-intensive protocols.
- add a timing arm to early-phase trials (e.g., morning versus evening infusion).
- Collect toxicity data and PROs such as EORTC-QLQ-C30 with administration times recorded.
- For oral drugs taken at home, integrate a sleep–wake diary + smartwatch into monitoring.
🧫 The Gut Microbiome: The Silent Regulator of Immunotherapy Response
The microbiome shapes antigen presentation, T-cell priming, and the tumor microenvironment. During ICI treatment (PD-1/PD-L1, CTLA-4), antibiotic exposure has been shown to weaken response, while selected microbiota profiles are associated with response.
- Evidence at a glance: early-phase melanoma and lung cancer FMT/probiotic intervention studies showed signals of overcoming resistance/restoring sensitivity.
- Practical benefit: prediction and personalization of response and toxicity management (e.g., colitis).
- add longitudinal stool metagenomic sampling (16S/WGS) to early-phase ICI protocols.
- Antibiotic use should be included in the protocol as a prespecified subgroup analysis.
- Dietary fiber intake and other confounders such as PPI use should be systematically recorded.
🧩 Rational Combinations and the Ownership Barrier
The synergy of drugs acting on different targets makes biological sense, but combining molecules owned by different companies is often prevented by contractual risk, uncertainty about toxicity and fear of comparison.
- Evidence at a glance: platform/factorial designs (e.g., I-SPY2, adaptive arms) provide efficient models for screening multiple combinations in research.
- Practical benefit: with fewer patients, early "signal detection" and balancing toxicity with efficacy.
- develop academic-led, multisponsor "neutral hub" contract templates.
- For early phases, define Bayesian adaptive designs and stopping rules.
- Real-world data (RWD) should be used to optimize combinations after approval (dose/sequence/schedule).
🧬 Genetic Ancestry: A Strategic Necessity for Equity and Efficacy
Biomarker frequencies and treatment response patterns vary with genetic ancestry . For example, EGFR mutations are more common in lung cancer patients of East Asian ancestry, while patients of African ancestry are often underrepresented in targetable biomarkers research.
- Evidence at a glance: ancestry differences have been associated with substantial variation in biomarker eligibility and outcomes.
- Practical benefit: more accurate patient selection, fewer false negatives/positives, and equitable access.
- include ancestry-based stratification and prespecified subgroup analyses in protocols.
- In multicenter studies, set representation targets (enrollment quotas).
- To reduce diagnostic errors, require quality standardization across laboratories and proficiency testing as conditions.
Other Problems Undermining Efficacy: Pricing and Repetition
Despite scientific progress in drug discovery, economic structures and ownership strategies present two major obstacles to treatment effectiveness: excessive pricing and lack of comparative evaluation. These can overshadow clinical benefits, particularly in the era of immunotherapy and targeted treatment.
📊 Immune Checkpoint Inhibitors: Prices and Copycat Density
| Molecule (target) | Manufacturer | Average Annual Cost (USD) | Clinical Effect (OS Gain, Months) | Number of Similar Molecules |
|---|---|---|---|---|
| Pembrolizumab (PD-1) | Merck | ≈ 150,000 | 4–6 months | 14 |
| Nivolumab (PD-1) | Bristol Myers Squibb | ≈ 145,000 | 4–6 months | 14 |
| Atezolizumab (PD-L1) | Roche | ≈ 130,000 | 3–5 months | 11 |
Sources: JAMA Health Forum 2024;5:e240142, IQVIA Oncology Report 2023.
💰 The Pricing Paradox
Most "new" drugs arise not from industry's own R&D, but from academic research supported by public funds (NIH, Horizon Europe, etc.). Once commercialized by the private sector, however, these drugs are sold at astronomical prices. More than 14 similar agents on the PD-1/PD-L1 axis show that competition has led to price alignment rather than price reductions.
- 🔹 Compared with 2000, the average oncology drug price has shown a 250% increase in cost.
- 🔹 Normalized for treatment duration, some agents have a monthly cost exceeding 20,000 USD per month.
- 🔹 Price increases are often independent of survival gains (4–6 months).
⚖️ Lack of Comparison: Which Is Better?
Despite multiple molecules targeting the same biological target, companies do not conduct direct comparative clinical trials . Physicians must therefore choose without knowing which agent is more effective or less toxic for the patient.
- 🔹 There are no direct comparisons between different PD-1 inhibitors.
- 🔹 For drugs acting on the same target, the absence of head-to-head clinical comparisons leaves the best choice for the patient uncertain.
- 🔹 Companies do not voluntarily support such trials to avoid the risk of "lower efficacy."
- independent international comparison consortia should be established (e.g., PD-1 Comparator Initiative).
- Regulators (FDA, EMA) should require postapproval head-to-head studies as a condition.
- National reimbursement systems should apply dynamic pricing according to the benefit–cost ratio of treatments.
Despite major advances in oncology treatment, making economic mechanisms transparent and establishing a culture of comparison between molecules are essential for fairer, more accessible cancer care in the future.
Conclusion and Outlook: Unlocking Oncology's True Potential
The point reached in cancer treatment is one of the greatest achievements in scientific history. Like every success, however, it has reached a moment of reassessment . Today's question is no longer "can we develop more drugs?" but "can existing drugs save more lives?"
"The secret of oncology's future lies not in new molecules, but in the right timing, the right patient, the right combination, and the right access."
— The Oncology of the Future Manifesto
The key strategies shaping oncology's future are becoming clear:
- 🔹 Data-driven individualization: chrono-oncology, genetic ancestry, and microbiome interactions should be integrated through real-time analyses.
- 🔹 A culture of scientific collaboration: transparent structures should allow data sharing between different companies and centers.
- 🔹 Equity in access: high drug prices should be redefined within the global principle of a "right to medicines."
- 🔹 Measuring long-term benefit: postapproval follow-up should include not only PFS, but quality of life, toxicity, and cost data.
💡 Final Word
Oncology is becoming more than the art of killing cells; it is the science of optimizing life . At the center of this transformation is seeing the patient not only as a biological system, but as an ecosystem of time, microbiota, and genetic balance . True innovation will come not from approving more drugs, but from using existing drugs more intelligently and more humanely in care.
📚 References
1️⃣ Classic Historical Studies
- Goodman LS, Wintrobe MM, et al. Nitrogen mustard therapy; use of methyl-bis (β-chloroethyl) amine hydrochloride and tris (β-chloroethyl) amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied disorders. JAMA 1946;132:126–132.
- Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-aminopteroyl-glutamic acid. N Engl J Med 1948;238:787–793.
- DeVita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in advanced Hodgkin’s disease. Ann Intern Med 1970;73:881–895.
- Pinkel D. Five-year follow-up of ‘total therapy’ in childhood lymphocytic leukemia. JAMA 1971;216:648–652.
- Einhorn LH, Donohue J. Cisplatin, vinblastine, and bleomycin in disseminated testicular cancer. Ann Intern Med 1977;87:293–298.
2️⃣ Clinical and Modern Oncology Sources
- Davies C, Goodwin J, Gray R, et al. Relevance of hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis. Lancet 2011;378:771–784.
- Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–358.
- André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–2351.
- Lee Y. Roles of circadian clocks in cancer pathogenesis and treatment. Exp Mol Med 2021;53:1529–1538.
- Fernandez E, Wargo JA, Helmink BA. The microbiome and cancer: A translational science review. JAMA 2025;333:2188–2196.
- Arora K, Suehnholz SP, Zhang H, et al. Genetic ancestry–based differences in biomarker eligibility for precision oncology therapies. JAMA Oncol 2025;11:310–316.
3️⃣ Reviews and Systematic Reviews
- Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med 2016;375:2369–2379.
- JAMA Oncology Editorial Board. Immuno-oncology drug approvals and comparative outcomes 2019–2024. JAMA Oncol 2024;10:1820–1832.
- IQVIA Institute. Global Oncology Trends 2023 – Outlook to 2028. IQVIA Report, May 2023.
- World Health Organization (WHO). Global Cancer Observatory, GLOBOCAN 2024 Database. https://gco.iarc.fr
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.